Business
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies FRAMINGHAM, MA / ACCESS Newswire / March 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, \"DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma,\" was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. \"These findings further illuminate the crucial role of NETs in limiting CAR T cell function and underscore the potential of DNase I as an adjunctive treatment to improve patient responses to immunotherapies. We continue to be encouraged by the growing body of positive preclinical data and believe that our approach has the potential to prolong survival compared to treatment with CAR T cell monotherapy, including CAR T therapies directed against solid tumors, where there has been only limited activity to date. We are committed to advancing our DNase development program forward and further exploring the translational potential of this combinatorial approach, and to provide patients with a much-needed alternative treatment option that has the potential to address several unmet needs in cancer treatment,\" commented Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic.For the preclinical study, co-administration of DNase I with CAR T cells was investigated in a syngeneic B16 murine melanoma model of lung metastasis. Bioluminescent ima...